LT2668184T - Azaindazolo arba diazaindazolo tipo dariniai kaip vaistai - Google Patents

Azaindazolo arba diazaindazolo tipo dariniai kaip vaistai

Info

Publication number
LT2668184T
LT2668184T LTEP12701884.4T LT12701884T LT2668184T LT 2668184 T LT2668184 T LT 2668184T LT 12701884 T LT12701884 T LT 12701884T LT 2668184 T LT2668184 T LT 2668184T
Authority
LT
Lithuania
Prior art keywords
azaindazole
medicament
derivatives
diazaindazole
type
Prior art date
Application number
LTEP12701884.4T
Other languages
English (en)
Lithuanian (lt)
Inventor
El Bachir Kaloun
Karim Bedjeguelal
Rémi RABOT
Anna Kruczynski
Philippe Schmitt
Michel Perez
Nicolas Rahier
Original Assignee
Pierre Fabre Médicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Médicament filed Critical Pierre Fabre Médicament
Publication of LT2668184T publication Critical patent/LT2668184T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
LTEP12701884.4T 2011-01-27 2012-01-27 Azaindazolo arba diazaindazolo tipo dariniai kaip vaistai LT2668184T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1150651A FR2970967B1 (fr) 2011-01-27 2011-01-27 Derives de type azaindazole ou diazaindazole comme medicament
PCT/EP2012/051283 WO2012101239A1 (en) 2011-01-27 2012-01-27 Derivatives of azaindazole or diazaindazole type as medicament

Publications (1)

Publication Number Publication Date
LT2668184T true LT2668184T (lt) 2018-04-10

Family

ID=44318089

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP12701884.4T LT2668184T (lt) 2011-01-27 2012-01-27 Azaindazolo arba diazaindazolo tipo dariniai kaip vaistai

Country Status (30)

Country Link
US (2) US20130172360A1 (2)
EP (1) EP2668184B1 (2)
JP (1) JP5931926B2 (2)
KR (2) KR20180122028A (2)
CN (1) CN103339129B (2)
AR (1) AR084935A1 (2)
AU (1) AU2012210467B2 (2)
BR (1) BR112013018852B1 (2)
CA (1) CA2823824C (2)
CY (1) CY1120088T1 (2)
DK (1) DK2668184T3 (2)
ES (1) ES2661695T3 (2)
FR (1) FR2970967B1 (2)
HR (1) HRP20180524T1 (2)
HU (1) HUE037153T2 (2)
IL (2) IL227496B (2)
LT (1) LT2668184T (2)
MA (1) MA34903B1 (2)
MX (1) MX356411B (2)
MY (1) MY180666A (2)
PL (1) PL2668184T3 (2)
PT (1) PT2668184T (2)
RS (1) RS57101B1 (2)
RU (1) RU2600976C2 (2)
SI (1) SI2668184T1 (2)
TN (1) TN2013000293A1 (2)
TR (1) TR201802944T4 (2)
TW (1) TWI546303B (2)
UA (1) UA109698C2 (2)
WO (1) WO2012101239A1 (2)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
EP2817292B1 (en) 2012-02-22 2019-12-18 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as tnap inhibitors
ES2704744T3 (es) 2012-06-13 2019-03-19 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
EP2689779A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10336707B2 (en) 2014-12-16 2019-07-02 Eudendron S.R.L. Heterocyclic derivatives modulating activity of certain protein kinases
MX373169B (es) 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US10211205B2 (en) * 2016-04-27 2019-02-19 International Business Machines Corporation Field effect transistor structure for reducing contact resistance
CN108570052A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元杂环并吡嗪化合物、制备方法、中间体、组合和应用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CA3098988A1 (en) 2018-05-02 2019-11-07 Jw Pharmaceutical Corporation Heterocycle derivative
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
EP3725777A1 (en) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- and pyrido-pyrazoles as protein kinase inhibitors
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021009568A1 (en) 2019-07-17 2021-01-21 2692372 Ontario, Inc. Benzenesulfonamide derivatives and uses thereof
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為fgfr抑制劑之雙環雜環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
EP4085061A1 (en) * 2019-12-31 2022-11-09 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021197467A1 (zh) * 2020-04-02 2021-10-07 上海华汇拓医药科技有限公司 多靶点的抗肿瘤化合物及其制备方法和应用
GB2617477A (en) * 2020-11-20 2023-10-11 2692372 Ontario Inc Benzenesulfonamide derivatives and uses thereof
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含fgfr抑制劑及nectin-4靶向劑之組合療法
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0970084T3 (da) * 1997-03-19 2003-09-29 Abbott Gmbh & Co Kg Pyrrolo[2,3-d]pyrimidiner og deres anvendelse som inhibitorer for tyrosinkinase
EP1215208B1 (en) 1997-10-27 2006-07-12 Agouron Pharmaceuticals, Inc. 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
AU2001262597B2 (en) 2000-06-22 2005-10-20 Pfizer Inc. Process for the preparation of pyrazolopyrimidinones
AU2003245700A1 (en) * 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
DE102004061288A1 (de) * 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
RU2008110941A (ru) * 2005-08-25 2009-09-27 Ф.Хоффманн-Ля Рош Аг (Ch) ИНГИБИТОРЫ КИНАЗЫ p38 МАР И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US20100056516A1 (en) 2006-07-17 2010-03-04 Williams Peter D 1-hydroxy naphthyridine compounds as anti-hiv agents
EP2120932B1 (en) 2006-12-20 2014-07-09 Nerviano Medical Sciences S.r.l. Indazole derivatives as kinase inhibitors for the treatment of cancer
PH12013501594A1 (en) 2007-07-20 2014-05-12 Nerviano Medical Sciences Srl Substituted indazole derivatives active as kinase inhibitors
EP2373626B1 (en) 2008-12-18 2016-08-24 Nerviano Medical Sciences S.r.l. Substituted indazole derivatives active as kinase inhibitors
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament

Also Published As

Publication number Publication date
HRP20180524T1 (hr) 2018-05-04
HUE037153T2 (hu) 2018-08-28
TWI546303B (zh) 2016-08-21
RU2600976C2 (ru) 2016-10-27
FR2970967B1 (fr) 2013-02-15
CY1120088T1 (el) 2018-12-12
TN2013000293A1 (en) 2015-01-20
BR112013018852B1 (pt) 2021-12-21
CA2823824A1 (en) 2012-08-02
ES2661695T3 (es) 2018-04-03
IL257748A (en) 2018-04-30
HK1186737A1 (en) 2014-03-21
AU2012210467A1 (en) 2013-09-12
IL257748B (en) 2020-06-30
RU2013138624A (ru) 2015-03-10
MX356411B (es) 2018-05-24
SI2668184T1 (en) 2018-06-29
NZ614432A (en) 2015-03-27
MY180666A (en) 2020-12-04
DK2668184T3 (en) 2018-03-12
EP2668184B1 (en) 2018-01-10
TR201802944T4 (tr) 2018-03-21
KR20140014147A (ko) 2014-02-05
UA109698C2 (xx) 2015-09-25
US8883821B2 (en) 2014-11-11
BR112013018852A2 (pt) 2017-08-15
KR20180122028A (ko) 2018-11-09
MX2013008673A (es) 2013-12-02
US20130172360A1 (en) 2013-07-04
PT2668184T (pt) 2018-03-13
US20130085144A1 (en) 2013-04-04
CN103339129A (zh) 2013-10-02
PL2668184T3 (pl) 2018-06-29
EP2668184A1 (en) 2013-12-04
KR101923751B1 (ko) 2018-11-29
AU2012210467B2 (en) 2016-07-07
IL227496A0 (en) 2013-09-30
FR2970967A1 (fr) 2012-08-03
CN103339129B (zh) 2015-07-29
MA34903B1 (fr) 2014-02-01
JP5931926B2 (ja) 2016-06-08
CA2823824C (en) 2018-12-11
JP2014503574A (ja) 2014-02-13
TW201247664A (en) 2012-12-01
WO2012101239A1 (en) 2012-08-02
AR084935A1 (es) 2013-07-10
RS57101B1 (sr) 2018-06-29
IL227496B (en) 2019-02-28

Similar Documents

Publication Publication Date Title
IL227496A0 (en) Derivatives of the azaindazole or diazaindazole types as medicine
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
HUE047354T2 (hu) Ivacaftor deuterizált származékai
PL3235812T3 (pl) Deuterowane pochodne iwakaftoru
ZA201306542B (en) 7-azaindole derivatives
ZA201501209B (en) Derivatives of azaindazole or diazaindazole type for treating pain
IL233081A0 (en) History of Betulin
PL2773648T3 (pl) Związki farmaceutyczne do zastosowania w terapii zakażenia clostridium difficile
SI2691083T1 (sl) Farmacevtski sestavek sitagliptina
SG11201400452TA (en) Derivatives of xanthone compounds
PL3287131T3 (pl) Terapeutyczne zastosowania ektoiny
ZA201305227B (en) Pharmaceutical composition comprising pyridone derivatives
EP2680843A4 (en) DERIVATIVES OF PYRAZOLSUBSTITUTED AMINO-HETEROARYL COMPOUNDS
EP2684869A4 (en) PREPARATION OF 3-MERCAPOTOPROPIONATES
ZA201404928B (en) Therapeutic use of imidazopyridine derivatives
PT2709584T (pt) Utilização sensorial dos derivados de 6-ciclopentilideno-hexano
EP2782902A4 (en) DERIVATIVES FROM PHENOXYISOBUTTERIC ACID
GB201100786D0 (en) Pharmaceutical compositions of immunosuppressants
GB201104632D0 (en) Use of medicament
EP2663302A1 (fr) Utilisation de la simalikalactone e comme agent anticancereux
GB201108673D0 (en) Colour stability of dual medicament dressings
AU2011900644A0 (en) Therapeutic Uses of SLIRP
GB201105302D0 (en) Treatment of acidosis
AU2011900519A0 (en) Drug compositions for the treatment of insomnia